SELLAS Life Sciences Group Inc buy michaelkr
Start price
28.12.25
/
50%
€2.35
Target price
-
Performance (%)
-
Price
-
-
Summary
This prediction has just been started. It does not have a price yet.SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
| Name | 1w |
|---|---|
| SELLAS Life Sciences Group Inc | - |
| iShares Core DAX® | 0.224% |
| iShares Nasdaq 100 | 0.371% |
| iShares Nikkei 225® | 0.972% |
| iShares S&P 500 | 0.417% |
Comments by michaelkr for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
Buy SELLAS Life Sciences Group Inc